Entero Therapeutics Inc.

NASDAQ: ENTO · Real-Time Price · USD
1.93
-0.23 (-10.65%)
At close: Aug 19, 2025, 3:59 PM
1.89
-2.07%
After-hours: Aug 19, 2025, 07:39 PM EDT

Entero Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a 29.27K 106.21K 537.4K
Gross Profit
n/a -29.27K -106.21K -537.4K
Operating Income
-15.62K -15.77M -12.68M -59.06M
Interest Income
n/a 2.53K 8.41K 1.17K
Pretax Income
-15.62K -15.79M -14.63M -58.54M
Net Income
-18.06M -15.79M -14.63M -58.54M
Selling & General & Admin
14.72K 10.74M 11.99M 18.38M
Research & Development
903.94 5.03M 691.26K 38.32M
Other Expenses
-0.00 n/a n/a 529.1K
Operating Expenses
15.62K 15.77M 12.68M 56.7M
Interest Expense
n/a 22.46K 15.88K 11.23K
Selling & Marketing Expenses
156K n/a n/a n/a
Cost & Expenses
15.62K 15.77M 12.68M 56.7M
Income Tax Expense
-0.00 n/a 126.56K 26.52M
Shares Outstanding (Basic)
4.65M 336.34K 35.91K 2.13K
Shares Outstanding (Diluted)
3.43M 336.34K 35.91K 2.13K
EPS (Basic)
-3.88 -46.96 -407.37 -27.54K
EPS (Diluted)
-5.26 -46.96 -407.37 -27.54K
EBITDA
-15.61K -15.74M -14.51M -57.99M
EBIT
-15.62K -15.77M -14.61M -58.53M
Depreciation & Amortization
48.95K 29.27K 29.27K 542.25K